New urine test directly detects AOD-9604 and other peptides with 50-500 pg/mL sensitivity
Background
The World Anti-Doping Agency (WADA) prohibits numerous low-molecular-mass peptides (<2 kDa) due to their performance-enhancing properties. This list includes growth hormone-releasing peptides (GHRPs), LHRH analogues, and fragments like AOD-9604 and TB-500. As the use of these substances grows, the number of samples requiring screening in sports drug testing has steadily increased. Traditional methods can be complex or lack the required sensitivity. The development of a streamlined, highly sensitive, and specific assay is crucial for maintaining the integrity of anti-doping controls and ensuring fair competition. This creates a need for methods that can simplify sample preparation while expanding the range of detectable peptides to keep pace with new performance-enhancing drugs.
Study Design
Researchers developed and validated a new analytical method for detecting 18 prohibited peptides, including AOD-9604. The method utilizes direct urine injection into a liquid chromatograph coupled with ion-mobility time-of-flight mass spectrometry (LC-IM-MS). The assay's performance was evaluated for precision, linearity (over a range of 0-10 ng/mL), and sensitivity. The stability of the peptides in urine was assessed to determine appropriate storage conditions. Finally, the method's real-world applicability was demonstrated by analyzing urine samples from individuals who had administered GHRP-6, GHRP-2, or LHRH in elimination studies, providing proof-of-concept.
Results
The new direct-injection LC-IM-MS method provided a facile, specific, and highly sensitive assay for all targeted peptides. The method achieved impressive limits of detection (LODs) between 50 and 500 pg/mL. This sensitivity is well below the minimum required performance level (MRPL) of 2 ng/mL set by anti-doping authorities, ensuring reliable detection.
The assay demonstrated excellent precision, with an imprecision of less than 20%, and showed linearity across the tested working range of 0 to 10 ng/mL. Stability testing confirmed that storing urine samples at -20°C is the appropriate temperature to preserve the integrity of the peptidic compounds for sports drug testing. The proof-of-concept was successful, as the assay correctly identified the administered peptides in elimination study urine samples, confirming its effectiveness in a practical setting.
Key Findings
- New LC-IM-MS assay achieves limits of detection between 50 and 500 pg/mL for 18 peptides.
- The method's sensitivity easily surpasses the required performance level of 2 ng/mL.
- The assay is precise, with an imprecision of <20% across the working range.
- Linearity was established for a working range between 0 and 10 ng/mL.
- Optimal storage temperature for preserving peptides in urine was determined to be -20°C.
Why It Matters
This simplified and highly sensitive testing method significantly enhances the ability of anti-doping agencies to detect a wide range of prohibited peptides like AOD-9604. For athletes using or considering these compounds, the risk of detection is now substantially higher and may extend for longer periods post-administration due to the low detection limits. This protocol streamlines laboratory workflows by eliminating complex sample preparation steps, allowing for higher throughput screening. The practical takeaway is that direct urine testing is now more powerful, making the use of these peptides in competitive sports a riskier proposition. The method appears ready for implementation in accredited laboratories, directly improving the current standard of sports drug testing without a long translational delay.
